GSK plc
No SEC Form 4 filings for $GSK in the last 30 days.
See all $GSK insider activity →GSK (LSE:GSK) filed for up to $3.05B in American Depositary Shares. Shares rose 3.59% to £18.16, with 1-year and 5-year returns at 15.52% and 56.52% respectively. Analysts suggest a 16% undervaluation, targeting £21.73, contingent on pipeline success and cost savings. Risks include pricing pressure and slower product ramp-up.
Berenberg maintains a buy rating on GSK, citing improved R&D returns and a strong pipeline. The stock is up 0.24% to 1,757.25 pence. Analysts note a 22% discount to peers and set a target price of 2,200 pence. GSK's growth drivers include Oncology and key trials for Ris-Rez, Mo-Rez, and Neladalkib.
GSK plans to cut 1,217 jobs in Belgium as part of a £1.9 billion cost-cutting initiative to align vaccine production with demand and protect profits ahead of patent expirations, including dolutegravir. The company will maintain most vaccine production and research in Belgium, focusing on high-priority programs like an mRNA flu vaccine, while consulting with unions.
Over the past 7 days, AlphAI's AI scored 55 news stories mentioning GSK (GSK plc). Coverage has skewed bullish: 24 bullish, 19 neutral, and 12 bearish.
Recent GSK coverage spans financial news, corporate actions and earnings.
The filing introduces potential dilution and raises capital for growth initiatives.
Bullish analyst stance tied to specific pipeline catalysts and a valuation discount narrative.
The announced savings plan may improve margins and support the share price.
The dividend declaration provides a short‑term catalyst for income‑focused investors and may generate modest buying pressure ahead of the ex‑date.
The delayed construction start and multi-year ramp can shift near-term capex timing and supply/delivery expectations for future respiratory and oncology medicines.
AlphAI scores every news story that mentions GSK with an AI model for sentiment and relevance, and aggregates insider trades from GSK plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
GSK (LSE:GSK) filed for up to $3.05B in American Depositary Shares. Shares rose 3.59% to £18.16, with 1-year and 5-year returns at 15.52% and 56.52% respectively. Analysts suggest a 16% undervaluation, targeting £21.73, contingent on pipeline success and cost savings. Risks include pricing pressure and slower product ramp-up.
2 min readBerenberg maintains a buy rating on GSK, citing improved R&D returns and a strong pipeline. The stock is up 0.24% to 1,757.25 pence. Analysts note a 22% discount to peers and set a target price of 2,200 pence. GSK's growth drivers include Oncology and key trials for Ris-Rez, Mo-Rez, and Neladalkib.
3 min readGSK plans to cut 1,217 jobs in Belgium as part of a £1.9 billion cost-cutting initiative to align vaccine production with demand and protect profits ahead of patent expirations, including dolutegravir. The company will maintain most vaccine production and research in Belgium, focusing on high-priority programs like an mRNA flu vaccine, while consulting with unions.
1 min readGSK announced a cash dividend of RUSD 0.4266 per unit for ISIN BRG1SKBDR008, payable on Oct. 15, 2026. The ex-dividend date is Aug. 12, 2026, according to the company.
1 min readGSK plans to start construction on an $800M biologics factory in Pennsylvania in 2027, with full operation by 2030. The project, part of a $1.2B U.S. investment, aims to create over 300 jobs and support research and development of respiratory and cancer treatments. GSK is also expanding a facility in Marietta, Pa., with a total investment of nearly $1.7B in the state.
4 min readGSK PLC is expected to report Q3 results in line with estimates, with vaccine sales weakness offset by HIV treatments and Nucala. RBC forecasts Q3 revenue of £8.82B, slightly below consensus, and core EPS of 50.8p, matching expectations. The broker maintained its Sector Perform rating and 1,975p price target. GSK is set to report results on 28 October.
2 min readBiotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.
2 min readOn July 17, 2026, GSK halted development of camlipixant, a lead drug for refractory chronic cough, despite positive phase 2b results. The decision followed mixed phase 3 trial outcomes, with the drug failing to meet primary endpoints in one trial and key secondary endpoints in both. GSK cited limited efficacy, unlikely to transform patient care. The drug was acquired by Bellus Health in a deal valued at about $2 billion.
2 min readGSK PLC (NYSE: GSK) announced an $800M investment to expand its Pennsylvania biopharmaceutical operations, creating 300 jobs. The company offers a 3.8% dividend yield with a 39% payout ratio, and its stock is fairly valued at $46.50. GSK has a GF Score of 77, indicating solid financial health and profitability.
3 min readThe UK government has launched a £48m partnership with Bristol Myers Squibb, GSK, and Gates Ventures to accelerate dementia research. The funding will support the BARBARA Alliance and create a platform for clinical trials. Prime Minister Andy Burnham aims to make the UK a leader in dementia research and treatment.
2 min read
